Skip to content

PP&E (Net) at other companies

Eli Lilly logo
Eli LillyLLY
$26.54B+43.7%
Amgen logo
AmgenAMGN
$8.22B+23.0%
Amylyx Pharmaceuticals, Inc. logo
Amylyx Pharmaceuticals, Inc.AMLX
$212K-74.0%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
$4.94M-26.2%
Nurix Therapeutics, Inc. logo
Nurix Therapeutics, Inc.NRIX
$21.7M+17.6%
Crinetics Pharmaceuticals logo
Crinetics PharmaceuticalsCRNX
$13.5M+6.9%

Other financials

Income statement

See full
Operating income-$27.3M-2.8%
Net income-$23.5M+1.5%
EPS (diluted)-$0.50+29.6%

Balance sheet

See full
Cash & equivalents$45.2M+51.2%
Total debt$555.0K+327%
Total equity$437.8M+85.9%
Total assets$452.7M+84.1%

Cash flow

See full
Operating cash flow-$20.2M+10.9%
CapEx$437.0K+1,357%
Free cash flow-$20.6M+9.1%

Valuation

See full
Market cap$2.21B+475%
Enterprise value$2.16B+533%

Returns & leverage

See full
Return on equity-25.7%
Debt / equity0.0×
Current ratio30.8×+7.5×

Where this comes from

Reported directly by MBX Biosciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:PropertyPlantAndEquipmentNet.

The official record: MBX Biosciences, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about MBX Biosciences, Inc.'s pp&e (net).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is MBX Biosciences, Inc.'s PP&E (net)?
MBX Biosciences, Inc. (MBX) reported PP&E (net) of $3.13M in Q1 2026.
How has MBX Biosciences, Inc.'s PP&E (net) changed year-over-year?
MBX Biosciences, Inc.'s PP&E (net) increased by 107.6% year-over-year, from $1.51M to $3.13M.
What is the long-term trend for MBX Biosciences, Inc.'s PP&E (net)?
Over 2 years (2023 to 2025), MBX Biosciences, Inc.'s PP&E (net) has grown at a 149.6% compound annual growth rate (CAGR), from $439K to $2.74M.
What does PP&E (net) mean?
Total property, plant, and equipment minus accumulated depreciation — the net book value of all tangible long-lived assets.